216 related articles for article (PubMed ID: 34083505)
1. The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies.
Yang C; Lou G; Jin WL
Signal Transduct Target Ther; 2021 Jun; 6(1):219. PubMed ID: 34083505
[No Abstract] [Full Text] [Related]
2. The promise of bispecific antibodies: Clinical applications and challenges.
Lim SM; Pyo KH; Soo RA; Cho BC
Cancer Treat Rev; 2021 Sep; 99():102240. PubMed ID: 34119803
[TBL] [Abstract][Full Text] [Related]
3. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
Shivarov V; Blazhev G
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
[TBL] [Abstract][Full Text] [Related]
4. The potential role of Bi-specific antibodies in acute myeloid leukemia.
Yilmaz M; Ravandi F
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101218. PubMed ID: 33279174
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts.
Ghalamfarsa F; Khatami SH; Vakili O; Taheri-Anganeh M; Tajbakhsh A; Savardashtaki A; Fazli Y; Uonaki LR; Shabaninejad Z; Movahedpour A; Ghalamfarsa G
Immunotherapy; 2021 Nov; 13(16):1355-1367. PubMed ID: 34641708
[TBL] [Abstract][Full Text] [Related]
6. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
7. [Bispecific antibodies in onco-hematology: Applications and perspectives].
Barrière S; El-Ghazzi N; Garcia M; Guièze R
Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
[TBL] [Abstract][Full Text] [Related]
8. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Demichelis-Gómez R; Pérez-Sámano D; Bourlon C
Curr Oncol Rep; 2019 Feb; 21(2):17. PubMed ID: 30715609
[TBL] [Abstract][Full Text] [Related]
10. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
11. Development and clinical application of bispecific antibody in the treatment of colorectal cancer.
Balibegloo M; Rezaei N
Expert Rev Clin Immunol; 2020 Jul; 16(7):689-709. PubMed ID: 32536227
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies catch cancer neoantigens.
Kingwell K
Nat Rev Drug Discov; 2021 May; 20(5):342. PubMed ID: 33785902
[No Abstract] [Full Text] [Related]
15. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in aggressive B-cell lymphomas.
Jacobson CA; Armand P
Best Pract Res Clin Haematol; 2018 Sep; 31(3):299-305. PubMed ID: 30213400
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
18. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibodies for Triple Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
